Perceptions of Saskatchewan community pharmacists regarding a prior-authorization program

Journal of Managed Care Pharmacy

Volumn 13, Issue 7, 2007, Pages 589-597

  Perepelkin, Jason ^a   Dobson, Roy Thomas ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Drug plan; Pharmacist; Policy; Prior authorization; Step therapy

Indexed keywords

ARTICLE; CANADA; COMMUNITY PROGRAM; CONTROLLED STUDY; DRUG INFORMATION; FEMALE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MALE; PHARMACIST; PHARMACY; PHYSICIAN; POPULATION RESEARCH; PRESCRIPTION; QUESTIONNAIRE;

EID: 35348941320     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.7.589     Document Type: Article

References (46)

1. Gross D. Prescription Drug Prices in Canada. Washington, DC: AARP Public Policy Institute; 2003.
2. Anis AH, Guh D, Wang X. A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care. 2001;39(4):315-26.
3. IMS. Pharmaceutical trends. Available at: http://www.imshealthcanada.com. Accessed October 23, 2006.
4. Canadian Institute of Health Information. Drug Expenditure in Canada 1985 to 2005. Ottawa, ON: Author 2006.
5. Rogers Media. Pharmacy Trends Report 2003. Available at: http://www.trendsreport2003.com. Accessed July 29, 2004.
6. Cooksey JA, Knapp KK, Walton SM, Cultice JM. Challenges to the pharmacist profession from escalating pharmaceutical demand. Health Aff. 2002;21(5):182-88.
7. Lewis S, Donaldson C, Mitton C, Currie G. The future of health care in Canada. BMJ. 2001;323:926-29.
8. Naylor CD. Health care in Canada: inercmentalism under fiscal duress. Health Aff. 1999;18(3):9-26.
9. Saskatchewan Health. Drug Plan and Extended Benefits Branch Annual Statistical Report 2005-2006. Regina, SK, Canada: Government of Saskatchewan; 2006.
10. Saskatchewan Health. 2007-2008 Saskatchewan Provincial Budget. Regina, SK: Government of Saskatchewan; 2007.
11. Hogerzeil H, Holloway K. How to promote quality use of cost-effective medicines. In: Freemanlle N, Hill S, eds. Evaluating Pharmaceuticals for Health Policy and Reimbursement. Malden, MA: Blackwell Publishing Ltd; 2004:174-89.
12. Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Amer J Manag Care. 2002;8(1):69-76.
13. Kielty M. Improving the prior-authorization process to the satisfaction of customers. Amer J Health Syst Pharm. 1999;56:1499-1501.
14. Loh E, Gosnell T, Poston J. Evaluation of Pharmacy Resources Required When Submitting Prescription Claims to Drug Plans. Ottawa, ON, Canada: Canadian Pharmacists Association; 1997.
15. Saskatchewan Health. Formulary - Fifty-Sixth Edition. Available at: http://formulary.drugplan.health.gov.sk.ca/. Accessed April 27, 2007.
16. Saskatchewan Health. Saskatchewan Health Exception Drug Status Request Form. Available at: http://www.forms.gov.sk.ca/he/getformharness.asp?formName= he602.xft&preference=PDFFORMS. Accessed June 28, 2007.
17. Larson L, Qualls B, Ward J. COX-II inhibitor prior-authorization process - the untold story (abstract). J Manag Care Pharm. 2001;7(5):366.
18. Cox E, Henderson R, Motheral B. Health plan member experience with point-of-service prescription step therapy. J Manag Care Pharm. 2004;10(4):291-98.
19. Dunn J, Cannon H, Mitchell M, Curtiss F. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12(4):294-302.
20. Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm. 2007;13(3):235-44.
21. Dillman DA. Mail and Internet Surveys: The Tailored Design Method. 2nd ed. New York, NY: John Wiley & Sons Inc.; 2000.
22. Angus DE, Karpetz HM. Pharmaceutical policies in Canada: issues and challenges. Pharmacoecon. 1998;14(suppl 1):81-96.
23. Anis AH. Pharmaceutical policies in Canada: another example of federal-provincial discord. Can. Med. Assoc. 2000;162(4):523-26.
24. Bacovsky RA, Virani R. Prior approval for drug program reimbursement - a cross-Canada review. Provin Reimburse Adv. 2004: 37-44.
25. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Amer J Manag Care. 2002;8(12):1041-54.
26. Deber RB, Hastings JEF, Thompson GG. Health care in Canada: current trends and issues. J Public Health Policy. 1991;12(1):72-82.
27. Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and general practitioners in the United Kingdom. Soc Sci Med. 2001;53:943-55.
28. Fullerton DSP, Atherly DS. Formularies, therapeutics, and outcomes: new opportunities. Med Care. 2004;42(suppl 4):III39-III44.
29. Giaquinta D. Session II: Drug formularies - good or evil? A view from a managed care provider. Cardiol. 1994;85(suppl 1):30-35.
30. Grasha AF. Pharmacy workload: the causes and confusion behind dispensing errors. Can Pharm J. 2001;134(3):26-35.
31. Hindmarsh KW. Optimal drug therapy: the role of the pharmacist in bridging the gap between knowledge and action. Can J. Clin Pharmacol. 2001;8(suppl A):53A-54A.
32. Jacobs P, Bachynsky J. Public Policies Related to Drug Formularies in Canada: Economic Issues. Working Paper 00-2. Edmonton, AB, Canada: Institute of Health Economics; 2000.
33. Kozma CM, Reeder CE, Lingle EW. Expanding Medicaid drug formulary coverage: effects on utilization of related services. Med Care. 1990;28(10):963-77.
34. LaPensee KT. Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. J Manag Care Pharm. 2003;9(1):36-44.
35. Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Amer J Manag Care. 2001;8(1):69-76.
36. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7(4):297-302.
37. Morgan S. Health Action: Building on the Legacy - Issues for Canadian Pharmaceutical Policy. Ottawa, ON, Canada: The National Forum on Health; 1998.
38. Rosser WW. The place of guidelines and their means of dissemination. Can J Clin Pharmacol. 2001;8(suppl A):34A-38A.
39. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care. 1990;28(10):928-39.
40. Rupp MT, Schondelmeyer SW. Prescribing problems and pharmacist interventions in community practice. Med Care. 1992;30:926-40.
41. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff. 2004;23(1):135-46.
42. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. The Milbank Quarterly. 1993;71(2):217-52.
43. Walser BL, Ross-Degnan D, Soumerai SB. Do open formularies increase access to clinically useful drugs? Health Aff. 1996;15(3):95-109.
44. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. Accessed 1997;25:230-39.
45. Perepelkin J. Pharmacists' experiences with the exception drug status (EDS) program in Saskatchewan [master's thesis]. September 2006. Available at: http://library2.usask.ca/theses/available/etd-09072005-091010/. Accessed October 20, 2000.
46. Saskatchewan Health. The Pharmaceutical Information Program. Available at: http://www.health.gov.sk.ca/ph_hisc_proj_pip.html. Accessed July 9, 2005.